• No results found

Cover Page The handle

N/A
N/A
Protected

Academic year: 2021

Share "Cover Page The handle"

Copied!
8
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

The handle

http://hdl.handle.net/1887/79824

holds various files of this Leiden University

dissertation.

Author: Salvagno, C.

(2)

IMMUNE CELL COMPLEXITY IN THE TUMOR

MICROENVIRONMENT OF BREAST CANCER

(3)

Cover concept: Camilla Salvagno and Giovanni Marinovich Cover design: Giovanni Marinovich

Lay-out and printing: ProefschriftMaken ISBN: 978-94-6380-439-4

The printing of this thesis was financially supported by the NKI-AvL.

© 2019 by Camilla Salvagno. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without prior permission of the author and the publisher holding the copyright of the articles.

(4)

IMMUNE CELL COMPLEXITY IN THE TUMOR

MICROENVIRONMENT OF BREAST CANCER

Proefschrift

ter verkrijging van de graad van Doctor aan de

Universiteit Leiden

op gezag van

Rector Magnificus

Prof. Mr. C.J.J.M. Stolker

volgens besluit van het College voor Promoties

te verdedigen op dinsdag

22 oktober 2019 klokke 11:15 uur

Door

Camilla Salvagno

Geboren te Venetië

(5)

Promotiecommissie:

Prof.dr. J. Borst

Prof.dr. J. Jonkers

(6)

Table of Contents

Chapter 1 11

Scope of the thesis

Unpublished

Chapter 2 27

Purification of Immune Cell Populations from Freshly Isolated Murine Tumors and Organs by Consecutive Magnetic Cell Sorting and Multi-parameter Flow Cytometry-Based Sorting

Camilla Salvagno and Karin E. de Visser

Methods Mol Biol. 2016;1458:125-35

Chapter 3 41

Transcriptional signatures derived from murine tumor-associated macrophages predict outcome in breast cancer patients

Sander Tuit*, Camilla Salvagno*,Theodore S. Kapellos*, Cheei-Sing Hau, Lea Seep, Marie Oestereich, Kathrin Klee, Karin E. de Visser, Thomas Ulas and Joachim L. Schultze

* These authors contributed equally

Manuscript submitted for publication

Chapter 4 79

Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy

Kelly Kersten†, Camilla Salvagno and Karin E. de Visser These authors contributed equally

Front Immunol. 2015 Oct 7;6:516.

Chapter 5 111

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

Camilla Salvagno, Metamia Ciampricotti*, Sander Tuit*, Cheei-Sing Hau, Antoinette van Weverwijk, Seth B. Coffelt, Kelly Kersten, Kim Vrijland, Kevin Kos, Thomas Ulas, Ji-Ying Song, Chia-Huey Ooi, Dominik Rüttinger, Philippe A. Cassier, Jos Jonkers, Joachim L. Schultze, Carola H. Ries and Karin E. de Visser

*These authors contributed equally

(7)
(8)

Referenties

GERELATEERDE DOCUMENTEN

The work described in this thesis was performed at the Division of Tumor Biology of the Netherlands Cancer Institute, Amsterdam, The Netherlands, and supported by grants from the

The research described in this thesis was performed at the Division of Tumor Biology of the Netherlands Cancer Institute (NKI/AvL) and supported by The Netherlands Organization

The work described in this thesis was performed at the Division of Tumor Biology of the Netherlands Cancer I nstitute, Amsterdam, The Netherlands. This work was supported by the

The work described in this thesis was performed at the Division of Cell Biology of the Netherlands Cancer Institute, Amsterdam, The Netherlands.. Aan

The work described in this thesis was performed at the Division of Tumor Biology of the Nether- lands Cancer Institute, Amsterdam, The Netherlands. This work was supported by

The studies described in this thesis were performed at the Department of Immunology at the Netherlands Cancer Institute (NKI), Amsterdam. This study was financially supported by

The research described in this thesis was performed at the Divisions of Molecular Biology and Immunology of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital

The research described in this thesis was performed at the Department of Immunology at the Netherlands Cancer institute (NKI-AVL) and was financially supported